Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
5–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Children aged 5-17 years (in Russia only: 12-17 years) with clinically stable chronic renal anemia
Hemodialysis for greater than or equal to (\>=) 8 weeks
Intravenous stable maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa for \>= 8 weeks before screening and with no weekly dose change \>= 25 percent (%) (increase or decrease) during the 2 weeks of screening
You may not be if
Overt gastrointestinal bleeding within 8 weeks before screening or during the screening period
Red blood cell (RBC) transfusions within 8 weeks before screening or during the screening period
Active malignant disease
Pure red cell aplasia (PRCA) or history of PRCA
Pregnant or lactating females
Sexually active participants: not willing to use reliable contraception during treatment and for 90 days following the end of treatment
